^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 exon 20 insertion

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC (NCI-2017-00831) (NCT03066206)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    03/17/2017
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EGFR • HER-2
    |
    EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 exon 19 mutation • HER-2 exon 23 mutation • HER-2 P780-Y781insGSP • HER-2 YVMA
    |
    Pozenveo (poziotinib)
    Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (FURMO-002) (NCT05364073)
    Phase 1
    ArriVent BioPharma, Inc.
    Recruiting
    Last update posted :
    05/20/2024
    Initiation :
    06/30/2022
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    HER-2
    |
    HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M
    |
    Ivesa (firmonertinib)
    Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration (ORIC-114-01) (NCT05315700)
    Phase 1/2
    ORIC Pharmaceuticals
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    03/10/2022
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    EGFR • HER-2
    |
    EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation
    |
    carboplatin • pemetrexed • enozertinib (ORIC-114)
    Her2-positive Lung Cancer Treated With Dedicated Drug (R2D2) (NCT03845270)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Completed
    Last update posted :
    12/19/2023
    Initiation :
    05/17/2019
    Primary completion :
    02/01/2021
    Completion :
    12/18/2023
    HER-2
    |
    HER-2 mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab)
    A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation (NCT05745740)
    Phase 1/2
    RemeGen Co., Ltd.
    Not yet recruiting
    Last update posted :
    11/27/2023
    Initiation :
    04/01/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2
    |
    HER-2 mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation
    |
    Irene (pyrotinib) • Aidixi (disitamab vedotin)
    A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (EXCLAIM) (NCT02716116)
    Phase 1/2
    Takeda
    Active, not recruiting
    Last update posted :
    10/18/2023
    Initiation :
    06/16/2016
    Primary completion :
    03/28/2025
    Completion :
    03/28/2025
    HER-2
    |
    EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation
    |
    carboplatin • pemetrexed • Exkivity (mobocertinib)
    Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer (NCT06067776)
    Phase 1
    Jonathan Riess
    Not yet recruiting
    Last update posted :
    10/05/2023
    Initiation :
    01/01/2024
    Primary completion :
    01/01/2025
    Completion :
    11/01/2026
    HER-2 • BRAF • ALK • MET • RET
    |
    EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation
    |
    Erbitux (cetuximab) • Tagrisso (osimertinib) • Tukysa (tucatinib)
    Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) (NCT05332561)
    Phase 2
    German Cancer Research Center
    Recruiting
    Last update posted :
    07/06/2023
    Initiation :
    06/29/2023
    Primary completion :
    03/01/2030
    Completion :
    12/01/2030
    HER-2 • PD-L1 • PIK3CA • TMB • BRCA1 • BRCA2 • PARP1 • TACSTD2
    |
    HER-2 positive • TMB-H • HR positive • MSI-H/dMMR • HER-2 negative • PIK3CA mutation • HER-2 exon 20 insertion • PALB2 mutation • HR positive + HER-2 negative • HER-2 exon 20 mutation
    |
    Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Perjeta (pertuzumab) • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)